|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kleeff J, Korc M, Apte M, La Vecchia C,
Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH,
et al: Pancreatic cancer. Nat Rev Dis Primers. 2:160222016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al Groupe Tumeurs Digestives of Unicancer, ;
PRODIGE Intergroup, : FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou P, Li B, Liu F, Zhang M, Wang Q, Liu
Y, Yao Y and Li D: The epithelial to mesenchymal transition (EMT)
and cancer stem cells: Implication for treatment resistance in
pancreatic cancer. Mol Cancer. 16:522017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sánchez-Tilló E, Liu Y, de Barrios O,
Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A
and Postigo A: EMT-activating transcription factors in cancer:
Beyond EMT and tumor invasiveness. Cell Mol Life Sci. 69:3429–3456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krebs AM, Mitschke J, Lasierra Losada M,
Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D,
Reichardt W, Bronsert P, et al: The EMT-activator Zeb1 is a key
factor for cell plasticity and promotes metastasis in pancreatic
cancer. Nat Cell Biol. 19:518–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh P, Wig JD and Srinivasan R: The Smad
family and its role in pancreatic cancer. Indian J Cancer.
48:351–360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Friess H, Yamanaka Y, Büchler M, Ebert M,
Beger HG, Gold LI and Korc M: Enhanced expression of transforming
growth factor beta isoforms in pancreatic cancer correlates with
decreased survival. Gastroenterology. 105:1846–1856. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Javle M, Li Y, Tan D, Dong X, Chang P, Kar
S and Li D: Biomarkers of TGF-β signaling pathway and prognosis of
pancreatic cancer. PLoS One. 9:e859422014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pantziarka P, Sukhatme V, Bouche G, Meheus
L and Sukhatme VP: Repurposing Drugs in Oncology
(ReDO)-itraconazole as an anti-cancer agent. E Cancer Med Sci.
9:5212015.
|
|
15
|
Hu Q, Hou YC, Huang J, Fang JY and Xiong
H: Itraconazole induces apoptosis and cell cycle arrest via
inhibiting Hedgehog signaling in gastric cancer cells. J Exp Clin
Cancer Res. 36:502017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tsubamoto H, Inoue K, Sakata K, Ueda T,
Takeyama R, Shibahara H and Sonoda T: Itraconazole inhibits
AKT/mTOR signaling and proliferation in endometrial cancer cells.
Anticancer Res. 37:515–519. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mamtani R, Yang YX, Scott FI, Lewis JD and
Boursi B: Association of itraconazole, a Hedgehog inhibitor, and
bladder Cancer. J Urol. 196:343–348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Antonarakis ES, Heath EI, Smith DC,
Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS,
Zhao M, et al: Repurposing itraconazole as a treatment for advanced
prostate cancer: A noncomparative randomized phase II trial in men
with metastatic castration-resistant prostate cancer. Oncologist.
18:163–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rudin CM, Brahmer JR, Juergens RA, Hann
CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P and Liu JO:
Phase 2 study of pemetrexed and itraconazole as second-line therapy
for metastatic nonsquamous non-small-cell lung cancer. J Thorac
Oncol. 8:619–623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim DJ, Kim J, Spaunhurst K, Montoya J,
Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, et al:
Open-label, exploratory phase II trial of oral itraconazole for the
treatment of basal cell carcinoma. J Clin Oncol. 32:745–751. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsubamoto H, Sonoda T, Yamasaki M and
Inoue K: Impact of combination chemotherapy with itraconazole on
survival of patients with refractory ovarian cancer. Anticancer
Res. 34:2481–2487. 2014.PubMed/NCBI
|
|
22
|
Inoue K, Tsubamoto H, Sakata K, Sakane R,
Hao H, Hirota S, Sonoda T and Shibahara H: Expression of Hedgehog
signals and growth inhibition by itraconazole in endometrial
cancer. Anticancer Res. 36:149–153. 2016.PubMed/NCBI
|
|
23
|
Hara M, Nagasaki T, Shiga K and Takeyama
H: Suppression of cancer-associated fibroblasts and endothelial
cells by itraconazole in Bevacizumab-resistant gastrointestinal
cancer. Anticancer Res. 36:169–177. 2016.PubMed/NCBI
|
|
24
|
Zhang D, Lei J, Ma J, Chen X, Sheng L,
Jiang Z, Nan L, Xu Q, Duan W, Wang Z, et al: β2-adrenogenic
signaling regulates NNK-induced pancreatic cancer progression via
upregulation of HIF-1α. Oncotarget. 7:17760–17772. 2016.PubMed/NCBI
|
|
25
|
Barone JA, Moskovitz BL, Guarnieri J,
Hassell AE, Colaizzi JL, Bierman RH and Jessen L: Food interaction
and steady-state pharmacokinetics of itraconazole oral solution in
healthy volunteers. Pharmacotherapy. 18:295–301. 1998.PubMed/NCBI
|
|
26
|
Guo J, Wang B, Fu Z, Wei J and Lu W:
Hypoxic microenvironment induces EMT and upgrades stem-like
properties of gastric cancer cells. Technol Cancer Res Treat.
15:60–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Carstens JL, Lovisa S and Kalluri R:
Microenvironment-dependent cues trigger miRNA-regulated feedback
loop to facilitate the EMT/MET switch. J Clin Invest.
124:1458–1460. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yin T, Wang C, Liu T, Zhao G and Zhou F:
Implication of EMT induced by TGF-beta1 in pancreatic cancer. J
Huazhong Univ Sci Technolog Med Sci. 26:700–702. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kong B, Michalski CW, Hong X, Valkovskaya
N, Rieder S, Abiatari I, Streit S, Erkan M, Esposito I, Friess H,
et al: AZGP1 is a tumor suppressor in pancreatic cancer inducing
mesenchymal-to-epithelial transdifferentiation by inhibiting
TGF-β-mediated ERK signaling. Oncogene. 29:5146–5158. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Javelaud D, Alexaki VI, Dennler S,
Mohammad KS, Guise TA and Mauviel A: TGF-β/SMAD/GLI2 signaling axis
in cancer progression and metastasis. Cancer Res. 71:5606–5610.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhong Y, Macgregor-Das A, Saunders T,
Whittle MC, Makohon-Moore A, Kohutek ZA, Poling J, Herbst BT,
Javier BM, Cope L, et al: Mutant p53 together with TGFβ signaling
influence organ-specific hematogenous colonization patterns of
pancreatic cancer. Clin Cancer Res. 23:1607–1620. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou X, Mao Y, Zhu J, Meng F, Chen Q, Tao
L, Li R, Fu F, Liu C, Hu Y, et al: TGF-β1 promotes colorectal
cancer immune escape by elevating B7-H3 and B7-H4 via the
miR-155/miR-143 axis. Oncotarget. 7:67196–67211. 2016.PubMed/NCBI
|
|
33
|
Wu M, Chen X, Lou J, Zhang S, Zhang X,
Huang L, Sun R, Huang P, Wang F and Pan S: TGF-β1 contributes to
CD8+ Treg induction through p38 MAPK signaling in
ovarian cancer microenvironment. Oncotarget. 7:44534–44544.
2016.PubMed/NCBI
|
|
34
|
Ellermeier J, Wei J, Duewell P, Hoves S,
Stieg MR, Adunka T, Noerenberg D, Anders HJ, Mayr D, Poeck H, et
al: Therapeutic efficacy of bifunctional siRNA combining TGF-β1
silencing with RIG-I activation in pancreatic cancer. Cancer Res.
73:1709–1720. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Aftab BT, Dobromilskaya I, Liu JO and
Rudin CM: Itraconazole inhibits angiogenesis and tumor growth in
non-small cell lung cancer. Cancer Res. 71:6764–6772. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim J, Tang JY, Gong R, Kim J, Lee JJ,
Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, et al:
Itraconazole, a commonly used antifungal that inhibits Hedgehog
pathway activity and cancer growth. Cancer Cell. 17:388–399. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang X, Wei S, Zhao Y, Shi C, Liu P, Zhang
C, Lei Y, Zhang B, Bai B, Huang Y, et al: Anti-proliferation of
breast cancer cells with itraconazole: Hedgehog pathway inhibition
induces apoptosis and autophagic cell death. Cancer Lett.
385:128–136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang G, Liu M, Wang Q, Shen Y, Mei H, Li
D and Liu W: Itraconazole exerts its anti-melanoma effect by
suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways.
Oncotarget. 8:28510–28525. 2017.PubMed/NCBI
|
|
39
|
Tsubamoto H, Sonoda T, Ikuta S, Tani S,
Inoue K and Yamanaka N: Combination chemotherapy with itraconazole
for treating metastatic pancreatic cancer in the second-line or
additional setting. Anticancer Res. 35:4191–4196. 2015.PubMed/NCBI
|
